866-997-4948(US-Canada Toll Free)

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Jun 2017

Category :

Pharmaceutical

No. of Pages : 1296 Pages

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2017, provides an overview of the Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline landscape.

Kidney cancer also called renal cancer is a disease in which kidney cells become malignant (cancerous) and grows out of control, forming a tumor. Symptoms include blood in urine, loss of appetite, fever that lasts for weeks, extreme fatigue, and anemia, shortness of breath and bone pain. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 16, 88, 82, 3, 75, 12 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 12, 5 and 11 molecules, respectively.

Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Cancer (Renal Cell Cancer) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 9
Kidney Cancer (Renal Cell Cancer) - Overview 10
Kidney Cancer (Renal Cell Cancer) - Therapeutics Development 11
Kidney Cancer (Renal Cell Cancer) - Therapeutics Assessment 48
Kidney Cancer (Renal Cell Cancer) - Companies Involved in Therapeutics Development 72
Kidney Cancer (Renal Cell Cancer) - Drug Profiles 157
Kidney Cancer (Renal Cell Cancer) - Dormant Projects 1233
Kidney Cancer (Renal Cell Cancer) - Discontinued Products 1246
Kidney Cancer (Renal Cell Cancer) - Product Development Milestones 1249
Appendix 1265

List of Tables
Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Products under Development by Companies, H1 2017 (Contd..10), H1 2017
Products under Development by Companies, H1 2017 (Contd..11), H1 2017
Products under Development by Companies, H1 2017 (Contd..12), H1 2017
Products under Development by Companies, H1 2017 (Contd..13), H1 2017
Products under Development by Companies, H1 2017 (Contd..14), H1 2017
Products under Development by Companies, H1 2017 (Contd..15), H1 2017
Products under Development by Companies, H1 2017 (Contd..16), H1 2017
Products under Development by Companies, H1 2017 (Contd..17), H1 2017
Products under Development by Companies, H1 2017 (Contd..18), H1 2017
Products under Development by Companies, H1 2017 (Contd..19), H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by 4SC AG, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by AbbVie Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Actuate Therapeutics Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Adaptimmune Therapeutics Plc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Aduro BioTech Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Advanced Cancer Therapeutics LLC, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Advenchen Laboratories LLC, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Affitech A/S, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Alethia Biotherapeutics Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Alkermes Plc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Altor BioScience Corp, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Ambrx Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Amgen Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Ampio Pharmaceuticals Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Apac Biotech Pvt Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Apcure SAS, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by APEIRON Biologics AG, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Aphios Corp, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by arGEN-X BV, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Argos Therapeutics Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by ARMO Biosciences Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by ArQule Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Astellas Pharma Inc, H1 2017
ney Cancer (Renal Cell Cancer) - Pipeline by AstraZeneca Plc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Bayer AG, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Berg LLC, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Bio-Cancer Treatment International Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Biocad, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Bionomics Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Bionovis SA, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Boston Biomedical Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Bristol-Myers Squibb Company, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Calithera Biosciences Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by CASI Pharmaceuticals Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by CBT Pharmaceuticals Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Celgene Corp, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Celldex Therapeutics Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Cellular Biomedicine Group Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Celyad SA, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Chipscreen Biosciences Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Cleave Biosciences Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by COARE Biotechnology Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Coherus BioSciences Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Corvus Pharmaceuticals Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Ecrins Therapeutics SAS, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Eisai Co Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Eli Lilly and Company, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Esperance Pharmaceuticals Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Exelixis Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Gene Techno Science Co Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Genentech Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Genor BioPharma Co Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by GlaxoSmithKline Plc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Glycotope GmbH, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Hemispherx Biopharma Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by HitGen LTD, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Horizon Pharma Plc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Hutchison China MediTech Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Ignyta Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Immune Design Corp, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Immune Pharmaceuticals Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Immunicum AB, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by ImmunoFrontier Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by ImmunoGen Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Immunomedics Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Immunomet Therapeutics Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Incyte Corp, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Innate Immunotherapeutics Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Innovation Pharmaceuticals Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Inspyr Therapeutics Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Johnson & Johnson, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by KAHR medical Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Karyopharm Therapeutics Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by KineMed Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Kite Pharma Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Komipharm International Co Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Konruns Pharmaceutical Co Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Lead Discovery Center GmbH, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Lidds AB, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Lion Biotechnologies Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Mabion SA, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by MacroGenics Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Mantis Therapeutics BV, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by MaxiVAX SA, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by MedImmune LLC, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Medinet Co Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Merck & Co Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Merck KGaA, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Mirati Therapeutics Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Molecular Partners AG, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Moleculin Biotech Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Monopar Therapeutics LLC, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Mount Tam Biotechnologies Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Mycenax Biotech Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by NanoSmart Pharmaceuticals Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by NantKwest Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by NBE-Therapeutics AG, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Nektar Therapeutics, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by NewLink Genetics Corp, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Novartis AG, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by NovaTarg Therapeutics Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Omeros Corp, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by OncBioMune Pharmaceuticals Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Oncobiologics Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Oncogenex Pharmaceuticals Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Oncolys BioPharma Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by OncoMax, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by OncoTherapy Science Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Oncovir Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Peloton Therapeutics Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Pfizer Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Pharma Mar SA, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Pharmicell Co Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Pivotal BioSciences Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Plexxikon Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Prima BioMed Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by PsiOxus Therapeutics Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Recombio SL, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Rexahn Pharmaceuticals Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Richter Gedeon Nyrt, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Sanofi, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Selvita SA, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Sevion Therapeutics Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Sillajen Biotherapeutics, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Sorrento Therapeutics Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Syndax Pharmaceuticals Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Synthon Holdings BV, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Systimmune Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Taiwan Liposome Company Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Taris Biomedical LLC, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by TC BioPharm Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Tocagen Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Tolero Pharmaceuticals Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by TRACON Pharmaceuticals Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by TVAX Biomedical Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Tyrogenex Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by UroGen Pharmaceuticals Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Valeant Pharmaceuticals International Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Vascular Biogenics Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Vault Pharma Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by Vaxeal Holding SA, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by ViiV Healthcare Ltd, H1 2017
Kidney Cancer (Renal Cell Cancer) - Pipeline by X4 Pharmaceuticals Inc, H1 2017
Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017
Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017 (Contd..1), H1 2017
Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017 (Contd..2), H1 2017
Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017 (Contd..3), H1 2017
Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017 (Contd..4), H1 2017
Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017 (Contd..5), H1 2017
Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017 (Contd..6), H1 2017
Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017 (Contd..7), H1 2017
Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017 (Contd..8), H1 2017
Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017 (Contd..9), H1 2017
Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017 (Contd..10), H1 2017
Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017 (Contd..11), H1 2017
Kidney Cancer (Renal Cell Cancer) - Dormant Projects, H1 2017 (Contd..12), H1 2017
Kidney Cancer (Renal Cell Cancer) - Discontinued Products, H1 2017
Kidney Cancer (Renal Cell Cancer) - Discontinued Products, H1 2017 (Contd..1), H1 2017
Kidney Cancer (Renal Cell Cancer) - Discontinued Products, H1 2017 (Contd..2), H1 2017

List of Figures
Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *